Alembic Pharmaceuticals DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.95×	0.97×	0.82×	0.97×	0.89×
	0.88×	0.87×	0.97×	0.96×	0.89×
	10.6%	10.9%	10.9%	10.6%	7.7%
	0.89×	0.89×	0.94×	0.99×	0.85×
	1.55×	1.55×	1.50×	1.34×	1.41×
	12.2%	12.6%	12.3%	13.1%	7.3%
	12.4%	12.4%	11.7%	13.4%	7.1%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

APLLTD₹794.85

Alembic Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersAJANTPHARM IPCALAB TORNTPHARM ALIVUS AKUMS AGARWALEYE ADVENZYMES AARTIPHARMMcap ₹15,623 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.89	0.97	0.82	0.97	0.95
Interest Burden (Pretax/EBIT) ×	0.89	0.96	0.97	0.87	0.88
EBIT Margin %	7.66	10.61	10.94	10.89	10.62
Asset Turnover ×	0.85	0.99	0.94	0.89	0.89
Financial Leverage (Assets/Equity) ×	1.41	1.34	1.50	1.55	1.55
ROE (5-step product, year-end total equity) %	7.28	13.09	12.28	12.56	12.19
ROE (owners' profit / average owners' equity) %	7.12	13.40	11.66	12.42	12.42

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.